JP2021523877A5 - - Google Patents

Info

Publication number
JP2021523877A5
JP2021523877A5 JP2020544255A JP2020544255A JP2021523877A5 JP 2021523877 A5 JP2021523877 A5 JP 2021523877A5 JP 2020544255 A JP2020544255 A JP 2020544255A JP 2020544255 A JP2020544255 A JP 2020544255A JP 2021523877 A5 JP2021523877 A5 JP 2021523877A5
Authority
JP
Japan
Prior art keywords
day
glp1r agonist
phenyl
agonist
glp1r
Prior art date
Application number
JP2020544255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523877A (ja
JPWO2019217165A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/030110 external-priority patent/WO2019217165A1/en
Publication of JP2021523877A publication Critical patent/JP2021523877A/ja
Publication of JP2021523877A5 publication Critical patent/JP2021523877A5/ja
Publication of JPWO2019217165A5 publication Critical patent/JPWO2019217165A5/ja
Priority to JP2024081189A priority Critical patent/JP2024112903A/ja
Pending legal-status Critical Current

Links

JP2020544255A 2018-05-08 2019-05-01 Ｇｌｐ１ｒアゴニストの治療的使用 Pending JP2021523877A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024081189A JP2024112903A (ja) 2018-05-08 2024-05-17 Ｇｌｐ１ｒアゴニストの治療的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862668384P 2018-05-08 2018-05-08
US62/668,384 2018-05-08
PCT/US2019/030110 WO2019217165A1 (en) 2018-05-08 2019-05-01 Therapeutic uses of glp1r agonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024081189A Division JP2024112903A (ja) 2018-05-08 2024-05-17 Ｇｌｐ１ｒアゴニストの治療的使用

Publications (3)

Publication Number Publication Date
JP2021523877A JP2021523877A (ja) 2021-09-09
JP2021523877A5 true JP2021523877A5 (https=) 2022-05-17
JPWO2019217165A5 JPWO2019217165A5 (https=) 2022-05-17

Family

ID=66484210

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544255A Pending JP2021523877A (ja) 2018-05-08 2019-05-01 Ｇｌｐ１ｒアゴニストの治療的使用
JP2024081189A Pending JP2024112903A (ja) 2018-05-08 2024-05-17 Ｇｌｐ１ｒアゴニストの治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024081189A Pending JP2024112903A (ja) 2018-05-08 2024-05-17 Ｇｌｐ１ｒアゴニストの治療的使用

Country Status (9)

Country Link
US (2) US20210023072A1 (https=)
EP (1) EP3790549A1 (https=)
JP (2) JP2021523877A (https=)
KR (2) KR20210005843A (https=)
AU (2) AU2019266114A1 (https=)
CA (1) CA3090823A1 (https=)
MX (1) MX2020008387A (https=)
SG (1) SG11202007966UA (https=)
WO (1) WO2019217165A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3157525A1 (en) 2019-10-25 2021-04-29 Gilead Sciences, Inc. Glp-1r modulating compounds
WO2021154796A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
TW202210486A (zh) * 2020-05-28 2022-03-16 中國大陸商杭州中美華東製藥有限公司 一種製備ｇｌｐ—１受體激動劑的方法
EP4213847A4 (en) * 2020-09-21 2024-12-04 vTv Therapeutics LLC AMORPHOUS FORM OF AN ISOQUINOLINE DERIVATIVE
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
EP4304711A1 (en) 2021-03-11 2024-01-17 Gilead Sciences, Inc. Glp-1r modulating compounds
PH12023552860A1 (en) 2021-04-21 2024-05-20 Gilead Sciences Inc Carboxy-benzimidazole glp-1r modulating compounds
KR102920994B1 (ko) 2024-05-20 2026-02-02 (주)인벤티지랩 오르포르글리포론 또는 이의 약학적으로 허용되는 염을 포함하는 마이크로 입자 및 이의 제조 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
US7727983B2 (en) 2008-03-07 2010-06-01 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
JP5755217B2 (ja) 2009-03-30 2015-07-29 トランステック・ファーマ，エルエルシー 置換アゾアントラセン誘導体、その医薬組成物とその使用の方法
WO2011031620A1 (en) * 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
EA201491749A1 (ru) * 2012-03-22 2015-01-30 ТРАНСТЕК ФАРМА, ЭлЭлСи Трис-(гидроксиметил)аминометановые соли низкомолекулярного агониста glp1r, их фармацевтические композиции и применение
SG10201704716XA (en) * 2013-01-17 2017-07-28 Vtv Therapeutics Llc Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders

Similar Documents

Publication Publication Date Title
JP2021523877A5 (https=)
US20250325536A1 (en) Therapeutic uses of glp1r agonists
CN101511364B (zh) 用于糖尿病的治疗组合
US8541456B2 (en) Roflumilast for the treatment of diabetes mellitus type 2
JP5910711B2 (ja) 併用医薬
JP2015044875A5 (https=)
JP2016518438A5 (https=)
JP2024515137A (ja) Ｇｐｒ４０アゴニスト及びｓｇｌｔ－２阻害剤を含む医薬組成物
JPWO2019217165A5 (https=)
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
KR20260027165A (ko) 의료 요법에서의 세마글루티드
CN116157132A (zh) 一种降低血糖的组合、应用和方法
US9241956B2 (en) Pharmaceutical preparation and method for treatment of diabetes
WO2006094942A1 (en) Roflumilast for the treatment of diabetes mellitus
RU2021130019A (ru) Состав низкодозовой тройной комбинации
JP2011105609A (ja) メトホルミンへの付加療法を含む２型糖尿病の治療方法